65,000 Shares in Bruker Corporation $BRKR Purchased by Sivik Global Healthcare LLC

Posted by Francis Steltz on Oct 13th, 2026

Sivik Global Healthcare LLC purchased a new position in Bruker Corporation (NASDAQ:BRKR – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 65,000 shares of the medical research company’s stock, valued at approximately $4,209,000. Bruker comprises approximately 2.6% of Sivik Global Healthcare LLC’s holdings, making the stock its 17th largest position.

Several other institutional investors and hedge funds have also made changes to their positions in BRKR. Pallas Capital Advisors LLC purchased a new stake in Bruker in the second quarter valued at approximately $570,746,000. Edmond DE Rothschild Holding S.A. acquired a new position in Bruker during the second quarter valued at $169,899,000. Primecap Management Co. CA acquired a new position in Bruker during the second quarter valued at $53,145,000. Bank of New York Mellon Corp purchased a new stake in Bruker in the second quarter valued at $44,839,000. Finally, Old West Investment Management LLC purchased a new stake in Bruker in the second quarter valued at $40,146,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BRKR has been the topic of several analyst reports. Barclays increased their price target on Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Guggenheim raised their target price on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Citigroup reduced their price target on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. The Goldman Sachs Group raised Bruker from a “strong sell” rating to a “strong-buy” rating in a report on Monday, September 21st. Finally, UBS Group assumed coverage on Bruker in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $59.79.

View Our Latest Stock Report on Bruker

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 27.20% of the company’s stock.

Bruker Price Performance

Bruker stock traded down $0.26 during trading on Tuesday, reaching $55.99. The company had a trading volume of 799,992 shares, compared to its average volume of 2,354,364. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The firm’s 50-day simple moving average is $58.48 and its 200 day simple moving average is $52.89. The firm has a market capitalization of $8.53 billion, a PE ratio of -80.01, a price-to-earnings-growth ratio of 1.80 and a beta of 1.22. Bruker Corporation has a 1-year low of $32.37 and a 1-year high of $66.98.

Bruker (NASDAQ:BRKR – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Monday, September 21st. Bruker’s dividend payout ratio is currently -28.57%.

About Bruker

(Free Report)

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.